10:26 AM EDT, 08/06/2024 (MT Newswires) -- Neumora Therapeutics ( NMRA ) shares were down 1.3% in recent Tuesday trading after the company reported a Q2 loss of $0.37 per diluted share, narrower than a loss of $1.28 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.37.

The clinical-stage biopharmaceutical company did not report any revenue for the quarter ended June 30.

Neumora said it had $371.6 million in cash, cash equivalents and marketable securities at the end of the quarter, which it said would enable it to fund its operating plan into 2026.

Price: 11.80, Change: -0.16, Percent Change: -1.34